by Rod Raynovich | Dec 27, 2010 | BIOgraph
Vermillion (VRML) continues its wild ride upward from the November low of $4.53 on heavy volume of 546K shares with no apparent news. Two analysts cover the stock with a buy/outperform and Revenue Forecasts in the $7M range for Year Ending Dec.’11 and a Price...
by Rod Raynovich | Nov 30, 2010 | BIOgraph
Restructuring Play in Diagnostics at a VC Valuation Vermilion(VRML) technology utilizes a panel of biomarkers integrated with multivariate analysis software to develop disease specific assays. The R&D effort leverages collaborations with institutions such as...
by Rod Raynovich | Oct 22, 2010 | BIOgraph
GE announced the purchase of Clarient (CLRT) for $5/share or $580M, a 34% premium over Clarient’s previous closing price. Revenues forecasted for 2011 and 2012 are at $114M and $136M respectively, pricing the deal at a Price to Sales of 4.25 to 5X. Revenues for...
by Rod Raynovich | Sep 23, 2010 | BIOgraph
Within the “diagnostics and tools” track at the Rodman and Renshaw Conference here are two interesting genomics companies that presented. Rosetta Genomics Ltd. (ROSG, $1.25) ,Market Cap $21M, Sh.Out. 16.5M Rosetta is an Israeli Company focused in...
by Rod Raynovich | Sep 20, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Continuing from Part 1 here are some specific comments on interesting companies. Adeona Pharmaceuticals (AEN) Amex ($0.83) Market Cap $19M, $25M Sh. Outstanding Adeona is a development stage drug Company focused in CNS that in -licenses clinical stage product...
by Rod Raynovich | Aug 2, 2010 | BIOgraph
The Wall Street Journal reported on Friday that Novartis (NVS) will collaborate with Pathwork Diagnostics on the development of biomarkers across a range of cancer types that would capitalize on the trend to “match patients with the right medicines”....
by Rod Raynovich | Jul 26, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors . A stock rally in the sector was ignited last week by earnings announcements from four major mid-cap...
by Rod Raynovich | Jul 6, 2010 | 2024-25 Life Science Portfolios, BIOgraph
But Path to Market is Still Rife with Hurdles Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization,...
by Rod Raynovich | Jun 14, 2010 | RAG
Genomics and Medicine: transformative therapies are coming but diagnostic breakthroughs will lead the way Ten years after the start of the Human Genome Project we have learned a lot about the links between genetics and disease but few direct cures have emerged. The...
by Rod Raynovich | May 12, 2010 | BIOgraph
Genotyping on a Fast Track Direct to Consumer Pathway Genomics is offering a “Health Kit” that reports your genetic risk for 70 diseases such as Cancer,Cardiovascular Disease,RA,and Diabetes. Disease carrier status is included as well as potential genetic...
